Scisparc

Scisparc Fixed Asset Turnover

The Fixed Asset Turnover of Scisparc (SPRC) as of Nov 12, 2026 is 23.63. In the previous year, Fixed Asset Turnover was 11.62 — a change of 103.38% (higher).

Fixed Asset Turnover

23.63

YoY

103.38%

Last updated:

Fixed Asset Turnover of Scisparc is 2022 23.63 . Fixed Asset Turnover of Scisparc was 2021 11.62 . It decreases by 103.38% higher compared to the previous year.

The Scisparc Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2017
9.74 USD
Jan 1, 2018
0.40 USD
Jan 1, 2019
2.85 USD
Jan 1, 2020
50.00 USD
Jan 1, 2021
11.62 USD
Jan 1, 2022
23.63 USD
The Scisparc Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
23.63+103.38%
11.62-76.76%
50.00+1,657.03%
2.85+615.50%
0.40-95.92%
9.74—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Fixed Asset Turnover of Scisparc is 23.63 in 2022.

Fixed Asset Turnover of Scisparc changed from 11.62 to 23.63, representing a 103.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Scisparc since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Scisparc with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Scisparc

All Key Metrics — Scisparc